Enrollment met in Asia PhIII liver cancer study of sorafenib vs radiation therapy

A man wearing a lab coat, purple medical gloves and eye protection
Clincial

A Phase III study of radiation therapy versus sorafenib (Nexavar) to treat unresectable hepatocellular carcinoma led by the National Cancer Centre of Singapore (NCCS), along with the Singapore Clinical Research Institute and Sirtex Medical, has completed enrollment for an Asia effort with results due in the first half of next year.

In a release, the NCCS said the liver cancer study called SIRveNIB evaluates Australia-based Sirtex Medical's internal radiation therapy SIR-Spheres Y-90 resin microspheres for efficacy and safety against current standard of care, sorafenib, with the branded product made by Bayer HealthCare.

"The Principal Investigator of this study is Professor Pierce Chow, a senior consultant surgeon at the NCCS," according to the release. "Besides the primary endpoint of overall survival in SIRveNIB, the team also looks at a comparison of the side effects and patient quality of life with these two very different approaches to treating unresectable HCC."

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The release said 360 patients are now enrolled at 27 centers across 10 Asia-Pacific countries including Singapore and New Zealand.

Sirtex, listed on the Australia Stock Exchange, had a roller-coaster ride last year that saw it soar above AU$50/share and then fall to levels around AU$20 after disappointing results of its Sirflox colorectal cancer treatment, though a secondary study showed positive signs that Sirflox helped treat liver tumors.

Shares are now quoted around AU$28.00.

- here's the NCCS site
 

Related Articles: 
Bayer's Nexavar falls short in new liver cancer trial
Bayer fails last-ditch attempt to block India's cheap Nexavar copies
Bayer keeps cheap Nexavar copy from being exported from India

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.